Recent updates clarify that the 2026 deadlines are projected dates based on the sponsor's annual cycle, so you should monitor the program page for official announcements. The research scope now explicitly prioritizes multidisciplinary approaches like multi-omics patient segmentation and fibrotic pathway modulation. Additionally, if you plan to partner with an academic institution, note that their indirect costs are now capped at 10%.
Funder: Crohn's and Colitis Foundation
Due Dates: March 30, 2023 (LOI, previous cycle) | July 24, 2023 (Full proposal, previous cycle) | May 31, 2026 (LOI/Preproposal) | August 14, 2026 (Full proposal)
Funding Amounts: Up to $450,000 per project per year; potential renewal for an additional year (total up to $900,000).
Summary: Supports companies developing non-surgical, translational therapies for fibrosis in IBD, with emphasis on clinical and multidisciplinary solutions for fibrostenosis.
Key Information: Only companies and product-focused organizations are eligible; academic collaborations allowed if directly tied to product development.